Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs

Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs

The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial fibrillation and a number of other conditions requi...

Full description

Saved in:

Bibliographic Details
Main Authors:	B. A. Tatarsky, N. V. Kazyonnova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2021-08-01
Series:	Российский кардиологический журнал
Subjects:	drug-drug interactions direct oral anticoagulants antiarrhythmic drugs atrial fibrillation cytochrome p450 glycoprotein p
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4482
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study
by: Victor Chien‐Chia Wu, et al.
Published: (2024-11-01)

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report
by: Yuki Miyata, et al.
Published: (2025-01-01)

Impact on Adherence and Clinical Outcomes of an Anticoagulation Stewardship Program in Users of Direct Oral Anticoagulants
by: Mayra A. Arenas-Beltrán, et al.
Published: (2025-04-01)

Antiarrhythmic drug use in atrial fibrillation among different European countries – as determined by a physician survey
by: Espen Fengsrud, et al.
Published: (2025-08-01)

Avoiding anticoagulation drugs for postoperative atrial fibrillation enabled successful conservative treatment of left atrial dissection: a case report
by: Kentaro Kiryu, et al.
Published: (2021-05-01)

ASSOCIATION OF RS2200733 POLYMORPHISM WITH ANTIARRHYTHMIC THERAPY AND PROGRESSION OF ATRIAL FIBRILLATION IN THE UZBEK POPULATIO
by: R. D. Kurbanov, et al.
Published: (2020-12-01)

Direct oral anticoagulants for electrical cardioversion
by: A. N. Volovchenko, et al.
Published: (2021-07-01)

Prognosis of Patients With Ischemic Stroke With Prior Anticoagulant Therapy: Direct Oral Anticoagulants Versus Warfarin
by: Kyeong‐Hyeon Chun, et al.
Published: (2024-08-01)

A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness
by: Carlo Maria Bellanca, et al.
Published: (2025-07-01)

The use of oral anticoagulants in patients with atrial fibrillation: cohort study data
by: O. V. Gaisenok, et al.
Published: (2016-09-01)

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case
by: R. F. Nasyrova, et al.
Published: (2018-12-01)

An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective
by: Malte Kuniss, et al.
Published: (2024-11-01)

Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
by: Nicola Ferri, et al.
Published: (2024-10-01)

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)
by: E. I. Baranova, et al.
Published: (2020-02-01)

Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants
by: S. R. Gilyarevsky, et al.
Published: (2023-07-01)

Pharmacogenetics of the safety of phenazepam in alcohol withdrawal syndrome: haplotype and combinatorial analyses of polymorphic variants in the pharmacokinetic factor genes
by: D. V. Ivashchenko, et al.
Published: (2020-04-01)

A potentially lethal interaction: Migraine, human immunodeficiency virus and ergotism – A primary care case report
by: Ahmad Sahli Mahzuz Ismail, et al.
Published: (2025-02-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

ADJUSTMENT OF PHARMACOLOGICAL ANTIARRHYTHMIC THERAPY IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION DURING SERIAL TESTING OF ANTIARRHYTHMIC DRUGS WITH TRANSESOPHAGEAL ELECTROPHYSIOLOGICAL STUDIES
by: K. A. Skiba, et al.
Published: (2003-06-01)

METABOLIC ACTIVITY STUDY IN PEOPLE WITH DRUG ALLERGY USING «COCKTAIL» PHENOTYPING METHOD
by: E. A. Egorenkov, et al.
Published: (2019-01-01)

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01)

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art
by: S. R. Gilyarevsky
Published: (2022-07-01)

A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models
by: Lara Marques, et al.
Published: (2025-06-01)

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016-07-01)

Antiarrhythmic therapy in the treatment of atrial fibrillation: yesterday, today, tomorrow
by: V. I. Podzolkov, et al.
Published: (2019-06-01)

Effectiveness of Class IC Antiarrhythmics in Patients with Paroxysmal Form of Atrial Fibrillation in Absence of Structural Heart Disease
by: D. A. Tsaregorodtsev, et al.
Published: (2023-05-01)

NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

INDI: a computational framework for inferring drug interactions and their associated recommendations
by: Assaf Gottlieb, et al.
Published: (2012-07-01)

Potential for anticoagulant therapy in the most vulnerable groups of patients
by: Irina A. Zolotovskaya, et al.
Published: (2022-02-01)

Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study
by: Hao Shi, et al.
Published: (2025-08-01)

Statins and their antiarrhythmic activity
by: N. Sh. Zagidullin, et al.
Published: (1970-01-01)

Prognosis of the influence of direct oral anticoagulants on the direct medical expenses in patients with atrial fibrillation
by: S. V. Malchikova, et al.
Published: (2020-08-01)

Historical Aspects of the Use of Antiarrhythmic Drugs in Clinical Practice
by: V. L. Doshchitsin, et al.
Published: (2022-07-01)

Safety of oral anticoagulants: focus on cerebral microbleeds
by: M. S. Chernyaeva, et al.
Published: (2025-05-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

Concomitant Drug Interactions With Non–Vitamin K Oral Anticoagulants Are Associated With Bleeding and Mortality Risk in Patients With Nonvalvular Atrial Fibrillation
by: Chun‐Ka Wong, et al.
Published: (2025-05-01)

Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice
by: Yu. P. Skirdenko, et al.
Published: (2022-03-01)

POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
by: B. A. Tatarsky, et al.
Published: (2014-12-01)

Personified approach to diagnostics and treatment of atrial fibrillation. Diagnostic stage (part 1)
by: E. A. Praskurnichii, et al.
Published: (2021-06-01)